Company acquires 55% stake in German heart device maker Occlutech
Alkem Laboratories is acquiring up to 55% of German cardiovascular device specialist Occlutech for approximately EUR 99 million (Rs 1,060 crore) as it builds out a global MedTech business targeting Rs 15,000 crore in revenues within five years. The question is, is this disciplined diversification or a distraction from the core generics business that won’t move the needle?
What Alkem Just Bought
Occlutech is a specialist provider of minimally invasive structural heart occlusion devices, treating congenital heart disease, stroke prevention, and heart failure. The company operates across over 70 countries with manufacturing facilities in Germany and Turkey, having sold more than 200,000 devices since inception.
The portfolio comprises over 10 product lines across three therapeutic areas. Revenue has grown at approximately 17% CAGR over CY22-24 to EUR 43 million (around Rs 430 crore), with estimates of EUR 49 million (Rs 490 crore) for CY25. Occlutech ranks as the third-largest player globally in the occluder segment—a niche but growing market within the USD 87 billion cardiovascular device industry.
Here’s the catch: Occlutech remains unprofitable. “CY25 revenue/EBITDA/loss at approximately EUR 49 million/EUR 2 million/EUR 6.8 million; margins remain in single digits (approximately 5%),” Motilal Oswal noted, adding that “Occlutech’s profitability has yet to improve despite over 15 years of presence in this space, primarily due to an enhanced focus on R&D.”
The company spent Rs 120 crore on R&D in CY24, with plans to increase this to Rs 150 crore including development of a left atrial appendage (LAA) product. For a business generating Rs 490 crore in revenue, that’s a 30% R&D intensity—typical for medical device innovation but a cash drain until products reach commercialization.
The Five-Year Plan
Alkem’s management laid out targets during the analyst day. “ALKEM has guided for overall MedTech revenue to reach Rs 15 billion, with an EBITDA margin of 22-25% over the next five years,” Motilal Oswal noted.
Breaking this down: Occlutech is expected to scale from Rs 490 crore currently to over Rs 1,000 crore in revenues. The orthopedic business—where Alkem acquired Bombay Ortho and is developing knee and hip implants—will contribute the balance. “Within the musculoskeletal space, ALKEM has set a target of 250,000 implants over the next five years and a 10% market share in India,” according to management commentary.
Geographic expansion is central to the plan. “ALKEM expects 45-46% of sales from EU and 20% from US in the Occlutech business over the next five years, from the current 71%/14% from EU/US,” Motilal Oswal noted. This implies aggressive market share gains in the US, where Occlutech currently holds just 5% in certain segments with targets of 25% over time.
From current EBITDA margins of 5%, management targets 20-25% at scale. “The company expects growth in revenues and profitability in the Cardiovascular segment through expansion of product portfolio, expanding markets and cost optimisation,” Nomura explained, citing drivers including “PFO occluder approval in the US, market share gain of ASD in the US (from 5% currently to approximately 25% over time), successful development and approval of left atrial appendage (LAA), cost optimisation and manufacturing shift to India.”
The Optimistic Case: Nomura’s View
Nomura sees the MedTech expansion as measured rather than reckless. “Management views the investment as limited and measured and is as unrelated as investments by generic pharmaceutical companies in innovation and biosimilars,” the brokerage stated.
The financial impact on Alkem’s consolidated earnings appears manageable. “The negative earnings impact is also likely to be less than 5% of Alkem’s consolidated earnings, on our assumptions,” Nomura noted, adding that “the investments are not significant considering Alkem’s current balance sheet and cash-generating potential.”
Operationally, Nomura believes MedTech won’t distract management from the core pharma business. “We think the business will be managed separately without any loss of management’s bandwidth,” the report stated.
The long-term prize justifies near-term losses, in Nomura’s assessment. “If executed well, the MedTech business may scale up and generate sustainable cash flows as the segment is sticky with high entry barrier,” the brokerage argued, maintaining its Buy rating and Rs 6,890 target based on 26x FY27 adjusted EPS of Rs 265.
Crucially, Nomura expects Alkem’s stock performance to remain driven by the pharma business. “We expect Alkem’s stock performance to be driven by the pharma business. The investments in MedTech are calibrated and are unlikely to be disruptive financially and operationally,” the report concluded.
However, profitability remains unproven. “Occlutech’s profitability has yet to improve despite over 15 years of presence in this space, primarily due to an enhanced focus on R&D,” Motilal Oswal cautioned, adding that “ALKEM intends to drive profitability by expanding its reach and accelerating product approvals/launches.”
The valuation multiple paid appears fair only if execution meets guidance. “The valuation appears decent, provided performance progresses in line with guidance,” Motilal Oswal stated. At 3.6x CY25 sales, the acquisition isn’t cheap for an unprofitable business, though it implies EV/EBITDA of approximately 15x/7x on CY28/CY30 EBITDA if margin targets are achieved.
For the overall Alkem story, Motilal Oswal sees limited upside. “ALKEM is diversifying its growth levers into the MedTech and CDMO space, in addition to its domestic formulations segment. On an overall basis, we expect 10.5%/12% CAGR in revenue/EBITDA over FY26-28. Earnings are expected to remain stable over FY26-28 due to a step-up in tax rate,” the brokerage noted, maintaining its Neutral rating as “the valuation adequately factors in the upside.”
